Pulmovant
pulmovant.com
Actively hiring
Information Technology
Biotechnology
Health Care
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3...
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascu...
Read more
Report
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p
Read more
Report
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026...
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of pati...
Read more
Report
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase
Read more
Report
Report
Pro access
Upgrade to see all 7 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Technologies
Tech DNA
Oracle
GCP
ChatGPT
Claude
AI/ML
GCP
ChatGPT
Claude
Machine Learning
Oracle
Other
SharePoint
ITSM
Stack modernity
86/100
How modern this stack is, based on technology relevance, AI adoption and the share of legacy tools.
In-demand technologies
GCP
3 jobs
Required
SharePoint
2 jobs
Required
Claude
1 job
Required
ChatGPT
1 job
Required
ITSM
1 job
Required
Machine Learning
1 job
Required
Oracle
1 job
Required
Salary medians are calculated from this company's open jobs and compared with the market.
Industry adoption
GCP
4%
Machine Learning
4%
Claude
3%
ChatGPT
2%
SharePoint
2%
Oracle
1%
Share of companies in the same industry that use each technology.
Stack changes
Oracle
Sep 2026
Machine Learning
Sep 2026
ITSM
Sep 2026
Claude
Sep 2026
ChatGPT
Sep 2026
SharePoint
Sep 2026
GCP
Sep 2026
Technologies recently added to or removed from this company's stack - a signal of tech migrations and new initiatives.
Nokia
Kaseya
StoneX Group
Applied Materials
Fuku
Merck & Co.
Growth
Hiring Momentum
56/100
Growing
Open positions
5
2 opened / 0 closed in 30 days
Median time-to-fill
33 days
faster than 38% of the market
ATS activity
Every ~3 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Field & Service
83% ▲
Public Policy
17% ▲
Actively hiring for Field & Service (+4 in 30 days)
Activity Timeline
Added Claude to stack
Sep 2026
Added ChatGPT to stack
Sep 2026
Added SharePoint to stack
Sep 2026
Added GCP to stack
Sep 2026
Offices
Where the company hires and what each office is for
Cities
6
Hiring now
0
Countries
2
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Waltham
United States
HQ
Pulmovant
303 Wyman St, Suite 300, Waltham, MA 02451
New York
United States
Regional office
Roivant Sciences
Philadelphia
United States
Regional office
Spirovant Sciences
Basel
Switzerland
Regional office
Emavant
Princeton
United States
Regional office
Princeton, NJ
Boston
United States
Regional office
Roivant Discovery